Dexaval N

Quick links to important sections

Dexaval N

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dexaval N

Property Description
Active Ingredient Dexamethasone, Neomycin
Form Ophthalmic suspension or ointment
Pharmacological Class Steroid-Antibiotic Combination
Common Use Managing inflammation and bacterial infection in the eye
Origin Synthetic (Dexamethasone) and Derived (Neomycin)

Defining Dexaval N: A Steroid-Antibiotic Combination Drug

Dexaval N is a specialized multi-component combination product, available as a prescription-only medicine, classified as a steroid-antibiotic combination intended for topical ophthalmic administration. This medication is supplied as either an ophthalmic suspension or an ophthalmic ointment, representing two distinct dosage forms intended exclusively for localized use on the eye. The combination format is clinically recognized for addressing conditions where both severe localized inflammation and the risk or presence of a susceptible bacterial infection must be simultaneously managed.

Core Components: What are Dexamethasone and Neomycin?

The preparation contains two distinct active ingredients INN: Dexamethasone and Neomycin. Dexamethasone is the corticosteroid component, functioning as a powerful synthetic agent to suppress localized inflammation and the associated immune response. Corticosteroids like dexamethasone work by decreasing swelling and redness. This means the medicine helps to quickly ease the primary physical signs of irritation. Neomycin is an aminoglycoside antibiotic, a compound derived from microbial sources, which provides bactericidal activity. Aminoglycosides disrupt protein synthesis in susceptible bacteria, thereby inhibiting their growth and survival. This confirms the component's role in actively fighting off specific bacterial causes of the condition. This fixed-dose combination offers a differentiating factor by preemptively merging the treatment pathways, unlike sequential administration of single agents.

General Purpose: Why is this Dual Action Necessary?

The general therapeutic purpose of Dexaval N is to capitalize on the complementary actions of its two components: the rapid reduction of often painful inflammation alongside the necessary elimination of an infectious source. This dual approach ensures that the inflammatory cascade, which can cause patient discomfort and potential tissue damage, is rapidly controlled by the corticosteroid. Concurrently, the aminoglycoside antibiotic prevents the proliferation of susceptible bacterial strains, thereby resolving the underlying infectious component. This characteristic reflects the clinical utility of combining anti-inflammatory steroids with broad-spectrum antibiotics in ophthalmic care.

Regulatory References

  1. Dexamethasone Ophthalmic: MedlinePlus
  2. MedlinePlus

What side effects are possible with Dexaval N?

Possible Side Effects and Safety Information

The safety profile of Dexaval N is officially documented through the classification of adverse reactions, which outlines the medicine's known risks. These risks are organized by the System-Organ Classes (SOC) of the body they affect, as reported in regulatory documents. Major SOCs involved include Metabolism and Nutrition Disorders, Musculoskeletal and Connective Tissue Disorders, Gastrointestinal Disorders, Nervous System Disorders, and Endocrine Disorders.

Adverse Reaction Classification

Official documents classify side effects based on their frequency, using terms like Common (e.g., fluid retention, headache, dizziness, increased blood pressure) and Rare (e.g., severe allergic reactions, specific eye problems). The regulatory framework highlights that the likelihood of many serious effects is often linked to higher doses (e.g., 6 mg/day or more) or longer duration of use.

Serious Safety Concerns

Serious Adverse Reactions (SARs) represent the most critical safety information. These documented events include Severe Allergic Reaction/Anaphylaxis, Gastrointestinal Bleeding/Perforation, Adrenal Insufficiency, Cushing’s Syndrome, and Severe Infections. This category focuses on risks that are considered life-threatening or require immediate medical intervention.

Population-Specific Safety Notes

The regulatory profile mandates caution for specific groups. In pediatric patients, long-term use is associated with a need to monitor growth and development. For pregnant and breastfeeding individuals, a formal risk assessment is required due to the potential for the medicine to affect the fetus or pass into breast milk.

Safety Limitations

Dexaval N is formally contraindicated in patients with systemic fungal infections or ocular herpes simplex infection. Extreme caution is also advised in patients with a history of untreated infections, peptic ulcer, diabetes, glaucoma, or osteoporosis, as the medicine's risk profile is heightened in these contexts. Abrupt discontinuation after prolonged use is restricted due to the risk of withdrawal syndrome and adrenal insufficiency.

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information

The information below is strictly based on documented statements within official government drug monographs (e.g., FDA Prescribing Information, EMA Summary of Product Characteristics) regarding Dexaval N overdose.

Documented Manifestations and Outcomes

Regulatory sources indicate that an overdose of Dexaval N is associated with specific clinical presentations, including drowsiness progressing to stupor, severe hypotension, and gastrointestinal distress. Severe outcomes explicitly listed include respiratory depression or arrest, profound coma, and cardiovascular collapse.

Population-specific notes indicate that pediatric patients may initially exhibit excitation, while geriatric patients may have increased susceptibility to profound central nervous system and cardiovascular depression.

Emergency Action and Management

Official instructions mandate that urgent medical help must be sought immediately following a suspected overdose. The instruction is to IMMEDIATELY contact a Poison Control Center. Furthermore, users are directed to call emergency services for any signs of breathing difficulty, severe confusion, or loss of consciousness.

Management as documented in regulatory texts is primarily supportive. No specific pharmacological antidote for Dexaval N is currently documented. Supportive care directives include maintaining a patent airway, continuous cardiac monitoring, frequent monitoring of vital signs, and serial laboratory measurements to manage symptomatic toxicity.

Therapeutic Uses of Dexaval N

What Dexaval N Treats: Main Uses and Benefits

This medication is commonly used to treat steroid-responsive inflammatory ocular conditions where a risk of bacterial infection exists. The dual-component preparation is applied across domains where additional symptomatic support is needed for symptoms related to inflammatory or irritative states.

Dexaval N is considered relevant for easing symptoms that create noticeable physiological strain in conditions like bacterial conjunctivitis, keratitis, chronic anterior uveitis, and inflammation following corneal injuries or postoperative management after eye surgery.

The primary benefit is that it helps address symptom clusters that may appear suddenly, relevant in contexts marked by both inflammation and infection. It supports the patient during difficult episodes by helping ease distress associated with pronounced redness and noticeable swelling (edema).

“It is often used when symptoms intensify and supportive relief is needed to manage both inflammation and infection risk.”

The medication may assist with maintaining a sense of stability during the healing process.


Quick Fact: Relief for Acute Ocular Inflammation

Conditions addressed: Inflammatory conditions with simultaneous bacterial infection risk, including uveitis and post-surgical care. Primary Symptom Benefit: Contributes to improved comfort by easing pronounced redness and swelling.

Eligibility and Restrictions for Use

Eligibility for Dexaval N

Dexaval N (a form of Dexamethasone) is a potent corticosteroid used for various conditions, but its use is strictly limited or prohibited in specific populations as defined by regulatory documents.

Contraindicated Populations

  • Systemic Fungal Infections: Use is generally prohibited due to the risk of exacerbating the infection, unless the corticosteroid is required to manage a severe drug reaction, such as to Amphotericin B.
  • Hypersensitivity: Patients with a known allergy to dexamethasone or any other component of the specific product must not use this medicine.
  • Epidural Administration: The use of this medicine via epidural injection is contraindicated due to the reported risk of severe neurological adverse reactions, including spinal cord infarction and stroke.

Use Requires Caution or is Not Recommended

Population/Condition Restriction Context (Official Labeling)
Infectious Disease Caution is advised for active/latent infections (e.g., tuberculosis, amebiasis, viral infections like ocular herpes simplex), as corticosteroids can reduce resistance, exacerbate existing disease, or mask signs of infection.
Gastrointestinal Risk Use with caution in patients with active or latent peptic ulcers, nonspecific ulcerative colitis, diverticulitis, or fresh intestinal anastomoses due to increased risk of perforation/hemorrhage.
Cardio-renal Status Caution is advised in patients with congestive heart failure, hypertension, or renal insufficiency due to the risk of fluid retention and electrolyte imbalance.
Pediatric Patients Prolonged use requires careful monitoring as it may cause suppression of growth in children and infants.
Pregnancy/Lactation Use in pregnancy requires weighing potential benefits against fetal risk. Mothers receiving pharmacologic doses are advised not to nurse as the drug may suppress infant growth.
Vaccination Avoid administering live or live attenuated vaccines to patients receiving immunosuppressive doses.

What should I know about interactions with other medicines?

The official regulatory profile for this ophthalmic combination details interactions across pharmacokinetic and pharmacodynamic domains.

Interaction Scope

The pharmacokinetic profile indicates that co-administration with strong systemic CYP3A4 inhibitors, such as ritonavir or cobicistat, leads to decreased clearance of the Dexamethasone component. This metabolic interaction increases the systemic exposure of the corticosteroid, which is officially stated to raise the potential for effects like adrenal suppression or Cushing's syndrome. Specific cautions are documented for children and predisposed patients regarding this increased systemic risk.

From a pharmacodynamic perspective, the combination includes several interaction-related restrictions. The concurrent use of this product with Topical NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) is noted in regulatory labels as potentially increasing the risk for corneal healing problems. Furthermore, due to the Neomycin component, caution is advised during co-administration with Botulinum Toxin Products because of the risk of potentiated neuromuscular effects.

Administration Timing Rules

A mandatory administration requirement is specified for administration alongside other eye medicines. If using other topical ophthalmic products, official documents require a minimum separation of five minutes between the applications to prevent dilution and ensure adequate drug concentration. The overall interaction structure, classified as requiring caution and monitoring, is based on both US FDA and European regulatory standards.

Mechanism of Action

How Dexaval N Works: Mechanism of Action


Inhibition of Farnesyl Pyrophosphate Synthase (FPPS)

Dexaval N is a nitrogen-containing bisphosphonate. Following its uptake by osteoclasts—the cells responsible for bone resorption—Dexaval N directly binds to and inhibits the activity of the enzyme farnesyl pyrophosphate synthase (FPPS) within the mevalonate pathway.


Mechanistic Cascade and Cellular Processes

The inhibition of FPPS prevents the synthesis of isoprenoid lipids, which are essential for the proper prenylation of small GTPases. This disruption in the prenylation of GTPases impairs crucial intracellular signaling pathways and cytoskeletal organization necessary for osteoclast function and survival.


System-Level Physiological Consequence

The resulting cellular impairment triggers the subsequent apoptosis of osteoclasts. This programmed cell death is the ultimate cellular mechanism by which Dexaval N acts to modulate the overall rate of osteoclast-mediated bone resorption.

Dosage and Administration Information

How to Use Dexaval N: Administration Guidelines

Dexaval N is a combination steroid and antibiotic medication intended exclusively for Topical Ophthalmic administration, meaning it is applied directly to the eye. The product is supplied in two distinct forms: an Ophthalmic Suspension (drops) or an Ophthalmic Ointment, and it is explicitly labeled as Not For Injection.


Dosing Regimens and Frequency

The general principle of use is to administer the medicine in a frequency pattern that is variable and dependent on the severity of the inflammatory condition. The administration schedule is as follows:

  • Standard Dose: Instill 1 to 2 drops of the suspension or apply an approximate 0.5-inch (~1.3 cm) ribbon of the ointment per dose.
  • Mild Disease: Use the dose up to 4 to 6 times daily.
  • Severe Disease: In the initial phase, the dose may be administered as frequently as hourly, with the frequency gradually reduced as the condition improves.

Procedural Instructions and Course Duration

Adherence to specific procedural rules is required for proper administration. The ophthalmic suspension must be shaken well immediately before each use. To prevent contamination, the container tip must not touch the eye, eyelid, or any other surface. If a patient is using multiple topical eye medications, a separation of at least 5 minutes between successive instillations is required.

The use of Dexaval N is structured around two key time constraints: the dosage must be tapered (reduced gradually) before final discontinuation. Furthermore, the initial prescription is typically limited to a small volume or weight (e.g., 20 mL or 8 g), and renewal without a follow-up examination is restricted. Safety and effectiveness have not been established in pediatric patients under the age of 2 years.

Recent Clinical Evidence

Research evidence / Overview of studies for Dexaval N

The research base for Dexaval N, a combination product containing a corticosteroid (dexamethasone) and an aminoglycoside antibiotic (neomycin), was studied for use in contexts where both inflammation and bacterial infection risk are present. The evidence primarily stems from clinical trials that monitor changes in physical signs and outcomes related to physical discomfort over defined observation periods.


Evidence for Managing Postoperative Ocular Inflammation and Infection Risk

Study Designs and Measured Outcomes

The core research context involves studies exploring inflammation that follows eye surgery, such as cataract extraction, while also exploring the prevention of post-surgical bacterial infection. Research examined the combination product in adult populations during these recovery periods. Studies explored outcomes linked to inflammatory or irritative states by monitoring objective markers, such as the flare and cell count in the anterior chamber of the eye. Studies also included monitoring of patient-reported outcomes describing perceived discomfort, such as pain and light sensitivity.

Findings describe patterns observed in the studies over the defined observation intervals. The evidence for this indication is largely provided by active-controlled Randomized Controlled Trials (RCTs), which compare the study medicine against another product used for the same purpose. The trials primarily monitored short-term effects, with outcome assessments generally being completed around one week (seven days) following the procedure.


What is Still Uncertain About Dexaval N: Research Gaps

Evidence highlights what is known—and what is still uncertain. Long-term effects are not fully established because the follow-up durations were limited in the primary clinical trials, focusing mainly on the acute period of treatment. Furthermore, data for certain groups remain limited, particularly for some age groups within the pediatric population. The study results reflect the specific conditions under which they were conducted and do not determine whether an individual will respond similarly.

Key Studies & References

  1. NEOMYCIN, POLYMYXIN B SULFATES, AND DEXAMETHASONE OINTMENT (Class Regulatory Information/Labeling)

Frequently Asked Questions (FAQ)

Common questions about Dexaval N (FAQ)

Q: Is Dexaval N the same as 'Dexaval' without the N?

The official product information for Dexaval N describes this dual-component medicine. Dexaval N is a combination product containing two active ingredients: Dexamethasone and Neomycin. The 'N' in the name typically refers to the Neomycin component, which is the antibiotic in this specific formulation.

Q: What happens if I forget to take Dexaval N one day?

Regulatory documents indicate that if a dose is missed, it should be applied when remembered. If it is almost time for the next application, the product information suggests skipping the missed dose and resuming the regular schedule. Extra or double doses are noted as not recommended by the manufacturer.

Q: What are the most common things people misunderstand about how to use Dexaval N?

Official guidance often highlights key procedural steps to help maintain the product's quality and concentration. Common warnings in patient counseling include the need to shake the suspension well before each use and the caution to avoid touching the container tip to the eye or any other surface to prevent contamination.

Q: Do studies show that Dexaval N affects energy levels?

The ophthalmic label does not directly list low energy as a common side effect. However, the active steroid component, Dexamethasone, can be absorbed into the body and may lead to systemic (body-wide) effects, such as signs of adrenal gland problems or muscle weakness, which can sometimes be perceived as tiredness or low energy.

Q: Is it normal to feel slightly nauseous when first starting Dexaval N?

While not always listed among the most common adverse reactions for the eye drop/ointment, the official product documentation does include nausea and vomiting as side effects that have been reported with this medicine. If symptoms are severe or concerning, standard medical guidance is to consult with a healthcare professional.

Q: Does Dexaval N have a known risk of dependence?

The regulatory information focuses on the risk of withdrawal syndrome and adrenal insufficiency if the product is discontinued abruptly after prolonged use. For this reason, official guidance requires the dosage to be gradually reduced (tapered) before final discontinuation.

Q: Is Dexaval N suitable for older adults (e.g., over 65)?

The regulatory label does not generally prohibit use in older adults. However, it specifically highlights the need for caution regarding conditions common in this age group, such as glaucoma. The official instructions state that monitoring of intraocular pressure (IOP) is necessary when the medicine is used for 10 days or longer.

Q: Is Dexaval N available as a generic medicine?

The active ingredients in Dexaval N are the generic substances, Dexamethasone and Neomycin. Official records indicate that generic versions of this combination product may be available from various manufacturers under different trade names.

Q: What does the term 'contraindication' mean in the context of Dexaval N?

A contraindication is a critical warning in the official documentation. It means that the medicine must not be used by a patient if they have a specific condition or characteristic, as the risk of serious harm outweighs any potential benefit. Examples for Dexaval N include having a systemic fungal infection or a known hypersensitivity to any of its components.

Q: Is it true that Dexaval N can cause changes in sleep patterns?

Official adverse reaction reports for systemic corticosteroids note that they can sometimes affect the central nervous system, leading to issues such as insomnia (trouble falling or staying asleep). If the steroid component is absorbed into the bloodstream, it may potentially contribute to changes in sleep patterns.

Q: What should be done if someone accidentally takes too much Dexaval N?

Official patient information advises that in the event of any accidental overdose or ingestion of the medicine, contact with a poison control center or emergency room is necessary for guidance. Since this is an eye medicine, accidental oral ingestion requires immediate attention.

Q: Does taking Dexaval N at a different time of day make a difference?

The official dosing information focuses on the required frequency of use (e.g., up to 4-6 times daily or hourly). The regulatory guidance does not specify that the time of day, such as morning versus night, makes a difference for the application.

Q: Is Dexaval N generally considered well-tolerated?

As an ophthalmic product, the medicine is typically prescribed for short durations for acute use. The adverse event profile reported in studies is generally limited to localized effects, which supports its use for acute, short-term treatment.

Q: What is the purpose of the 'inactive ingredients' listed in Dexaval N?

Inactive ingredients are substances that are not medically active in treating the condition but are essential for the product. They are necessary for the formulation, stability, and proper delivery of the medicine. This may include preservatives, buffering agents, and components that ensure the drops or ointment have the right consistency.

Q: What is the official definition of 'short-term use' versus 'long-term use' for Dexaval N?

Regulatory documents do not provide a fixed number of days for all patients, but they define a period of heightened risk. The label specifies that if the medicine is used for 10 days or longer, routine monitoring of intraocular pressure (IOP) is required due to the risk of eye damage. This duration serves as a point of clinical distinction.

Q: Are there any specific activities, like driving, that need caution while on Dexaval N?

Due to the topical nature of the medicine, the official patient information cautions that it may cause temporary blurred vision or other visual changes immediately after application. Official warnings note that driving or operating machinery is not advised until any temporary visual changes have resolved.

Q: Why is Dexaval N classified as a prescription-only medicine?

The medicine is classified as prescription-only primarily due to the potency of the steroid component and the need for medical supervision. This supervision is required because of the associated risks, including the potential for glaucoma (increased pressure in the eye) and the chance of developing secondary infections.

Q: Do I need to fast or eat before taking Dexaval N?

No, there are no instructions regarding food or fasting. Since Dexaval N is a topical ophthalmic medicine that is applied directly to the eye, its effectiveness is not affected by what you eat or when you eat.

How should Dexaval N be stored and disposed of?

How to Store and Dispose of Dexaval N?

Strict storage and handling requirements must be followed to maintain the product's stability and integrity, as defined by regulatory documents.

Storage Conditions

Requirement Specification
Temperature Store at 20 to 25 C (68 to 77 F), corresponding to Controlled Room Temperature.
Protection The product must be protected from light and freezing. Do not expose the medicine to heat or autoclave the container.
Packaging Single-dose vials must remain in their original container until the time of use.

Stability and Disposal

Dexaval N vials are intended for single use. After the prescribed dose is withdrawn, any unused portion remaining in the single-dose vial must be discarded according to established procedures. It is critical to adhere to the defined storage temperature and light-protection requirements to ensure the product remains stable.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dexaval N found in:

A-Z Index: